Partnership Opportunities
Optinose has developed innovative devices that transform treatment by leveraging the nose for drug delivery in a manner that addresses traditional nasal administration.
Using known molecules, Optinose deepens and broadens tissue penetration, offering the potential to tackle previously intractable challenges, such as delivery across the nose-brain barrier, without deposition to the lung.
Who Should Contact Optinose?
- Pharmaceutical and biotechnology companies interested in evaluating the nasal polyps or migraine applications
- Those seeking an innovative, non-oral, or non-injected delivery platform for their proprietary CNS, systemic, or topical nasal compounds
- Companies seeking to re-evaluate promising compounds that experienced clinical development challenges due to insufficient oral bioavailability, first-pass metabolism, or speed of onset
- Companies seeking to find new or improved uses for existing compounds
The Company offers both single and multi-use intranasal delivery devices for powder and liquid formulations.
Our Purpose
The Optinose team is unified by a common shared mission: to improve lives.
Company History
As an ear, nose, and throat (ENT) surgeon and clinician specializing in nasal and sinus diseases, Per Djupesland experienced firsthand the limitations of existing nasal drug delivery options.